Pierre-Jean Lamy, PharmD, PhD, of the Medical Institute of Genomic Analysis, Montpellier, France, discusses recent developments around the use of circulating tumor (ct)DNA as a biomarker, providing a non-invasive substitute for biopsies. Speaking at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, Dr Lamy discusses the limitations, next-steps and exciting new developments in the application of ctDNA in the detection and diagnosis of cancer.

свернуть